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Seventy percent of newly diagnosed bladder cancers are classiﬁed as non-muscle-invasive bladder cancer (NMIBC) and are often
associated with high rates of recurrence that require lifelong surveillance. Currently available treatment options for NMIBC
are associated with toxicities that limit their use, and actual practice patterns vary depending upon physician and patient
characteristics. In addition, bladder cancer has a high economic and humanistic burden in the United States (US) population
and has been cited as one of the most costly cancers to treat. An unmet need exists for new treatment options associated with
fewercomplications,betterpatientcompliance,anddecreasedhealthcarecosts.Increasedpreventionofrecurrencethroughgreater
adherence to evidence-based guidelines and the development of novel therapies could therefore result in substantial savings to the
healthcare system.
1.Introduction
Non-muscle-invasive bladder cancer (NMIBC), formerly
known as superﬁcial bladder cancer, is a common, hetero-
geneous disease associated with high rates of recurrence and
that often requires lifelong surveillance [1–4]. Treatment op-
tions for NMIBC are limited, with initial management
involving transurethral resection of the bladder tumor
(TURBT), followed by adjuvant instillations of chemother-
apy or immunotherapy to reduce recurrence rates and pre-
vent disease progression [3]. Commonly used current intra-
vesical therapies include mitomycin C—a naturally occur-
ring product of Streptomyces bacteria that has antibacterial
and antitumor properties—and bacillus Calmette-Gu´ erin
(BCG), an attenuated mycobacterium that produces an
inﬂammatoryreactioninthebladder.Bothofthesetherapies
were introduced several decades ago and have been shown
to reduce recurrence rates. Each of the intravesical therapy
options has associated toxicities that can impair patient
compliance, particularly so for BCG, which routinely causes
irritative voiding symptoms, often causes fever and malaise,
and in rare cases, results in systemic sepsis [5–9].
Clinical guidelines for NMIBC aim to guide clinicians to
appropriate use of intravesical therapy; however, guidelines
from the diﬀerent associations vary in their recommenda-
tions, so the physician’s subjective assessment of the beneﬁts
and the patient’s preferences (such as acceptability of risk)
cansupersedetheavailableevidencefavoringtheuseofintra-
vesical therapy [10–16]. As a result, real-world utilization of
intravesical therapy often falls below the recommendations,
resulting in potentially preventable bladder cancer recur-
rencesandassociateddownstreamconsequences,suchasdis-
ease progression and reduced quality of life [17, 18]. Cystec-
tomy is typically reserved for patients with high-risk NMIBC
who elect for early, aggressive surgical intervention, for those
who have failed intravesical therapy, and for those who have
progressed to muscle-invasive disease [10, 12, 14, 19–24].
In addition to the clinical burden of bladder cancer,
the disease is associated with a high economic burden,2 Advances in Urology
accounting for the highest lifetime treatment costs per pa-
tient of all cancers due to its high recurrence rate, long-term
survival rate, and costs associated with disease surveillance
and treatment [25, 26]. Potentially preventable recurrences
duetounderuseofintravesicaltherapymayaddsubstantially
to the cost of caring for patients with NMIBC [27].
TherearemanyunmetneedsinthetreatmentofNMIBC,
which contribute to its burden on both patients and society.
Thus, the objective of this paper is to qualitatively review the
societal and economic burden associated with the disease in
the USA and to describe the shortcomings of currently avail-
able NMIBC treatments. This paper will underscore the need
for new treatment options that are associated with fewer
complications, better patient compliance, increased utiliza-
tion in appropriate settings, and lower healthcare costs.
2. Methods
This qualitative review was conducted by applying a list of
search terms to a database of the medical sciences (Pub-
Med, published by the National Library of Medicine). The
set of search terms included variations of “bladder cancer,”
“NMIBC,” “BCG,” “mitomycin,” “intravesical therapy,” “cys-
tectomy,” “epidemiology,” “risk factors,” “guidelines,” “eﬃca-
cy,” “clinical burden,” “toxicity,” “diagnostic,” “health-related
quality of life,” and “economic burden.” Articles were exclud-
ed if they were published in languages other than English. A
total of 98 articles were identiﬁed, abstracted, and evaluated
using the Oxford Center for Evidence-Based Medicine’s 2011
levels of evidence [28]. The majority of those were then used
in this paper to describe current treatment options, the clini-
cal and economic burden of NMIBC, and unmet needs of
NMIBC that exist today.
3. Overview of NMIBC
The bladder is a vessel that stores urine produced by the
kidneys before excretion [4]. The bladder itself is made up of
several tissue layers. The ﬁrst 2 layers include the urothelial
and the lamina propria layers. The urothelial or mucosal
layer makes contact with the bladder contents, while the
lamina propria, or submucosal layer, connects the urothelial
layer to the underlying smooth muscle [4]. Bladder cancer is
a common malignancy arising from the urothelial cells and
is responsible for considerable morbidity and mortality [2].
The most common symptom of bladder cancer is hematuria,
which occurs in 80% to 90% of patients [4]. Approximately
70% of newly diagnosed cases of bladder cancer are NMIBC,
meaning that they are conﬁned to the urothelial and lamina
propria layers of the bladder [3, 4, 26, 29–32]. Among
NMIBCs, around 70% present as Ta lesions (papillary tumor
conﬁned to the urothelium), 20% as T1 lesions (tumor inva-
des the lamina propria), and 10% as carcinoma in situ (CIS)
(ﬂat, high-grade tumor conﬁned to the urothelial layer)
[4, 29].
NMIBC tends to require lifelong surveillance, due pri-
marily to the fact that disease recurrence occurs frequently,
even in those patients treated with TURBT and existing
intravesical therapies [3, 6–8, 13, 14, 24, 32–45]. TURBT is
the standard initial treatment option for NMIBC, which can
be performed with or without intravesical chemotherapy, as
aone-timeimmediatepostoperativeinstillation[35,46].The
most commonly used medication for perioperative instilla-
tion is mitomycin C. TURBT is both diagnostic and thera-
peutic, and the procedure provides critical staging informa-
tion [35]. TURBT may be followed by an induction course
(withorwithoutsubsequentmaintenancecourses)ofintrav-
esical therapy, given as a series of treatments over several
weeks [35, 46]. The current intravesical treatment options,
such as BCG and mitomycin C, are associated with side
eﬀects,complications,andalackaconsistentroleinthether-
apy of NMIBC and often go underutilized.
4.Epidemiology andRiskFactors
Bladdercancerisoneofthemostcommonlydiagnosedmali-
gnancies in the USA, with an estimated 70,530 new cases
diagnosed in 2010 [1]. Its eﬀect on mortality is also substan-
tial, with a projected 14,680 deaths that same year [1]. How-
ever, in terms of stage distribution, bladder cancer has a 5-
year relative survival rate—which measures the survival of
the cancer patients in comparison to the general popula-
tion—of97%forinsitu,71%forlocal,35%forregional,and
5% for distant cases [47].
B l a d d e rc a n c e rc o m m o n l ya ﬀects the elderly, with the
median age of 73 years at diagnosis [47]. Bladder cancer inci-
dence varies in terms of gender and ethnicity. The lifetime
risk of developing bladder cancer is 3.81% for males and
1.18% for females, and the risk escalates with increasing age
[1]. Bladder cancer is the fourth-most-common cancer in
men in terms of new cases, with an incidence 4 times higher
than women (37.9 versus 9.6 per 100,000) [1]. In terms of
ethnicity, the incidence of bladder cancer is approximately 2
t i m e sh i g h e ri nw h i t em e nt h a ni nA f r i c a nA m e r i c a nm e ni n
the USA, although African Americans tend to present at a
higher stage and with a lower median survival [1, 48].
Riskfactorsforbladdercancerincludecigarettesmoking;
work-relatedcontactwithcyclicchemicals(e.g.,benzeneand
arylamines); and exposure to dyes, rubbers, textiles, and
paints[4,49,50].Cigarettesmoking isthenumber-one envi-
ronmental risk factor, attributable to 50% to 66% of bladder
tumors in men and 25% in women [4]. Genetic factors also
appear to inﬂuence the risk of developing bladder cancer,
possibly through metabolism of environmental carcinogens
[49].
5. ClinicalOutcomes of NMIBC
ImportantclinicaloutcomesinthenaturalhistoryofNMIBC
include recurrence and progression. Patients with NMIBC
have a high risk for disease recurrence (i.e., tumors of the
same stage and grade as primary tumor), or disease progres-
sion (i.e., a higher stage with muscle invasion or metastasis
throughout the clinical course of treatment), even in those
treatedwithTURBTandexisting intravesicaltherapies[3,6–
8, 13, 14, 24, 32–45]. Nearly one-third of patients withAdvances in Urology 3
NMIBC will have a recurrence of disease within 2 years, and
patients often require routine monitoring and treatment for
the rest of their lives [2, 15, 26, 31, 46, 51–56].
There are several diﬀerent ways to categorize a patient’s
risk of recurrence. For example, the European Organization
for Research and Treatment of Cancer (EORTC) has provid-
ed risk tables, which allow calculation of an NMIBC patient’s
probability of recurrence and progression after TURBT [14].
The calculation is based on 3 clinical factors (number of
tumors,tumor size, prior recurrencerate)and 3 pathological
factors (T category, CIS, tumor grade) [20]. The total score is
then calculated, and each patient falls into a low-, intermedi-
ate-, and high-risk group for the recurrence and progression
risk groups [14]. It is important to note that the 5-year risk
of progression to advanced disease and recurrence has been
reported to range from 1% to 45% and 31% to 78%, res-
pectively, in patients with NMIBC [51]. Even though adju-
vant intravesical chemotherapy does not remove all the risk
of recurrence, it is still essential to consider it in all patients
to decrease the risk of recurrence [14].
In addition to recurrence and progression, complications
of disease surveillance and treatments can contribute to the
clinical burden. Disturbances in a patient’s urinary habits are
often noticed (including urinary tract complications such as
infection, inﬂammation, urinary incontinence, urinary obs-
truction, renal insuﬃciency, and bladder perforation) [2].
6. Treatment of NMIBC
Considerations for appropriate treatment options in non-
muscle-invasive disease must be made in conjunction with
clearly deﬁned goals—namely, to prevent disease recurrence
and progression to muscle-invasive disease and to avoid the
loss of the bladder [4]. The standard initial treatment sup-
ported for NMIBC is TURBT, which can be performed on an
outpatient basis with general anesthesia [13, 14, 16, 35, 57].
The most common side eﬀects associated with TURBT are
bleeding and infection [4]. To prevent tumor recurrence,
TURBT may be followed by an immediate postoperative
instillation of chemotherapy (e.g., mitomycin C, epirubicin,
and doxorubicin) and/or an adjuvant course of intravesical
chemotherapy or immunotherapy (e.g., BCG). The typical
adjuvant course consists of a 6-week induction (to induce
remission) of intravesical chemotherapy given via a urethral
catheter and left in the bladder for a speciﬁc amount of time,
usually 1 to 2 hours [4, 7, 13]. In addition, a patient may go
on to receive a maintenance regimen, typically consisting of
3 weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months
from start of induction [8].
The antibiotic chemotherapeutic agent mitomycin C is
considered a standard of care for bladder instillations after
TURBT [3]. One study of patients with low-risk NMIBC
(stage Ta and T1 disease) found that single-dose mitomycin
C resulted in a signiﬁcantly lower early recurrence rate (11%
versus 21% for placebo) within the ﬁrst 24 months follow-
ing initial TURBT [58]. Another study was performed with
502 patients (stage Ta or T1 disease) randomized after
TURBT to either no further treatment, 1 instillation of
mitomycinCimmediatelypostoperatively,or1instillationof
mitomycin C immediately postoperatively plus intravesical
instillations at 3-month intervals for a year [59]. After a
median follow-up of 7 years, a single instillation of mito-
mycin C decreased tumor recurrence by 50% compared with
those patients who did not receive any intravesical therapy
[59]. Thus, in patients with NMIBC at low risk of recurrence
and progression, 1 immediate instillation of chemotherapy is
recommended after TURBT [14]. Use of immediate instilla-
tion of chemotherapy after TURBT is discussed in more
detail here in after under the section Treatment Guidelines
for NMIBC.
Mitomycin C is commonly administered at dosages of
20 to 60mg weekly for 6 to 8 weeks and in some instances
followed by maintenance therapy monthly for a year [4].
Even though some literature has suggested that maintenance
therapy enhances the eﬀectiveness of mitomycin C induction
in preventing tumor recurrence, its role is still uncertain
[13,16].Forexample,accordingtoTolleyetal.,therewasnot
conclusive evidence that 5 instillations of mitomycin C for
ay e a ro ﬀered signiﬁcant beneﬁt over the single instillation
[59]. According to a meta-analysis involving mitomycin C,
thiotepa, and epirubicin, a short intensive schedule of instil-
lationswithintheﬁrst3to4monthsafteranimmediateinsti-
llation may be as eﬀective as longer-term treatment sched-
ules [60]. Also, higher drug concentrations and providing
drug concentration optimization in the bladder have been
suggested to potentially provide better results [60]. Thus,
data examining duration and frequency of instillations of
intravesical chemotherapy for patients whose disease has
recurred are generally inconsistent and do not support use
of any chemotherapy treatment longer than 1 year [14, 16].
Mitomycin C has a high molecular weight, resulting in
a low incidence of systemic side eﬀects [4]. In particular,
the most common adverse eﬀect of mitomycin C is chemical
cystitis,whichhasbeenreportedinupto41%ofpatients[7].
The manifestations of cystitis include dysuria, frequency, ur-
gency, suprapubic pain, and discomfort. In addition, the in-
cidence of decreased bladder capacity has been as high as
22% in clinical trials, with the rare need for cystectomy due
toseverebladdercontractures[61].Less commonadverseef-
fects include eczema-like reactions (4% to 12%) and myelo-
suppression, which is rare [5].
In addition to mitomycin C, 4 other immediate intraves-
ical chemotherapy agents are available and used in the USA:
doxorubicin, epirubicin, thiopeta, and valrubicin. Mito-
mycinC,epirubicin,anddoxorubicinallhavesimilareﬃcacy
within the setting of immediate intravesical instillation to
mitomycin C [45]. The anthracycline antibiotic-related che-
motherapy agents include doxorubicin, epirubicin, and val-
rubicin. Their mechanism of action involves DNA inactiva-
tion and the production of activated oxygen radicals to inter-
fere with cancer cell function [7]. Valrubicin is speciﬁcally
indicated for use in patients with BCG-refractory CIS; how-
ever, it plays no role in the treatment of NMIBC in Europe
[13]. Epirubicin and valrubicin may have a slight advan-
tage with fewer side eﬀects compared to doxorubicin but
havesimilarsideeﬀectsasmitomycinC[7].Upto50%ofpa-
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symptoms of chemical cystitis [7]. Local toxicity seems to
be lower with epirubicin and valrubicin and includes cystitis,
dysuria, and increased urinary frequency and urgency [5].
Thiotepa is another option for immediate instillation but is
rarelyusedintheUSAbecauseofitsassociatedriskofmyelo-
suppression [57].
New drug delivery systems, such as electromotive drug
administration (EMDA), have been explored in order to
enhance the eﬀectiveness of intravesical chemotherapy [62].
In a randomized study comparing passive mitomycin C to
EMDA mitomycin C for patients with high-risk NMIBC,
time to recurrence was prolonged to 35 months with EMDA,
compared with 19.5 months with passive mitomycin C (P =
0.013) [63]. Further study is warranted to assess the feasibil-
ity of implementing EMDA in the larger uro-oncologic com-
munity.
As an adjuvant agent, the intravesical immunotherapy
agentBCGiscommonlycitedasthesuperiorchoiceforhigh-
riskpatientsduetothebeneﬁt/riskproﬁle.Inameta-analysis
that compared mitomycin C versus BCG in patients with
intermediate- or high-risk NMIBC, those patients receiving
BCGinductionwithmaintenancesawa32%reductioninthe
risk of recurrence compared to those receiving mitomycin
C( P<0.0001), while there was a 28% increase in the risk
of recurrence (P = 0.006) for BCG in the trials without
BCG maintenance [64]. In another meta-analysis, a 27%
reduction in the odds of progression was demonstrated with
theadditionofBCGmaintenancetreatmentforpatientswith
NMIBC (P = 0.0001) [65]. The size of the reduction was
similar in patients with Ta and T1 papillary tumors and in
those with CIS [65]. Because of these data, the European
Association of Urology (EAU) recommends that in those pa-
tients with tumors at high risk of progression, at least 1 year
of maintenance therapy with BCG is indicated [14].
Even though maintenance therapy with BCG has been
shown to be more eﬀective than chemotherapy at preventing
recurrences in patients with tumors at high risk of progres-
sion, the widespread use of BCG is limited due to its adverse
eﬀect proﬁle [3, 7, 12–14, 20, 23, 30, 35, 41, 43, 66].
BCG is associated with complications spanning from mild
fever, hematuria, hepatitis, cystitis, and tuberculosis to life-
threatening sepsis [5–9, 31]. Most importantly, one-third
of eligible patients starting BCG completed the full 3-year
maintenance treatment schedule, with 20% stopping treat-
ment because of BCG toxicity [67]. Since the major compli-
cations appear after systemic absorption, BCG should not be
administered during the ﬁrst 2 weeks after TURBT, when the
risk of systemic absorption is highest [14]. Therefore, BCG
has no role in the immediate postoperative setting [59].
When deciding on the optimal treatment option for
NMIBC, there should be careful consideration of the pa-
tients’ risk of recurrence and progression, along with the side
eﬀects of each treatment. While all of these chemotherapeu-
ticinstillationstosomedegreemaybesafeandeﬀectiveatre-
ducing recurrence risk in the short term, recurrences remain
common in the long term. As a result, patients must be
monitored at intervals, because these recurrences are asso-
ciated with a substantial economic burden for the healthcare
system, a decrement in the quality of life for patients, and,
ultimately, leave the patients at risk for a poor cancer control
outcome [3].
Radical cystectomy is the standard of care for BCG-refra-
ctory CIS and serves as an option for patients with NMIBC
who have high-risk disease and desire aggressive interven-
tion, who have recurred after intravesical therapy, or who
haveprogressedtomuscle-invasivedisease;however,itsuseis
associated with a 3% risk of mortality and a 28% to 60% risk
of morbidity [10, 12, 22, 24, 31, 33, 36, 38, 68–70]. Further-
more, it is an invasive surgical procedure, associated with a
highriskofinfectionandbleeding,alengthyrecoveryperiod,
and signiﬁcant alterations in body image and urinary, sexual,
and gastrointestinal function [4].
New agents that reduce the short-term risk of recurrence
with improved safety and eﬃcacy are needed for those with
superﬁcial bladder cancer. One of these promising agents in
development for the management of NMIBC is apaziquone.
Apaziquone, an indolequinone chemotherapeutic agent, has
shown little systemic absorption or toxicity when used intra-
vesically and had activity similar to mitomycin C, BCG, and
epirubicin when tested against low-grade marker lesions. In
a marker lesion study, the complete response rate after6 con-
secutive instillations of apaziquone in patients with superﬁ-
cial bladder cancer was 67% (95% conﬁdence interval [CI]:
51%, 80%) [71]. Local side eﬀects were shown to be similar
to those due to mitomycin C and epirubicin, but less severe
and less frequent compared to BCG [71].
Other agents that are being investigated include gemc-
itabine and docetaxel. Gemcitabine has been shown to have
high response rates, with complete response rates of 46.4%
among those with superﬁcial bladder cancer [72]. However,
patients are not disease-free for an extended period of time,
with 67.8% of patients experiencing recurrence during the
ﬁrst year [72]. In a phase 1 trial, docetaxel demonstrated a
complete durable response in 22% of patients and a median
disease-free survival of 13.3 months [73].
7. Treatment Guidelinesfor NMIBC
Current treatment guidelines support the use of a single dose
of adjuvant intravesical chemotherapy for low-risk patients
withNMIBCbecauseofitsabilitytoreducetheriskoftumor
recurrence [14, 16]. A meta-analysis of 7 randomized clinical
trials found a 39% decreased odds of recurrence at a median
follow-up of 3.4 years in patients who received a single
postoperative instillation of chemotherapy versus patients
receiving TURBTalone [45].In 2005, a reviewby aninterna-
tional consensus panel found that the risk of recurrence can
be reduced by 50% at 2 years and by 15% or more at 5 years
with a single dose of adjuvant intravesical chemotherapy
[43]. Accordingly, the panel recommended a single dose of
intravesical chemotherapy, ideally within 6 hours, and no
more than 24 hours after TURBT, with the exception of
patients with a suspected bladder perforation [43].
For patients with a small-volume, low-grade Ta bladder
cancer, the American Urological Association (AUA) guide-
lines advance an initial single postoperative dose of intravesi-
calchemotherapyasanoption [16].TheEAUrecommends1Advances in Urology 5
immediate postoperative instillation of chemotherapy to re-
duce the risk of recurrence in all eligible Ta and T1 tumors
[14].
Despite the recommendation of immediate intravesical
chemotherapy in current treatment guidelines, actual use is
thought to be low, with estimates varying widely. A study of
14,677 bladder cancer patients undergoing TURBT between
1997and2004foundthatonly49(0.33%)receivedintravesi-
cal chemotherapy within 24 hours [15]. Whereas, according
todatafromtheSurveillance,Epidemiology,andEndResults
(SEER) Program from 2004 to 2007, only 6.7% of patients
diagnosed with Ta bladder cancer received an intravesical
perioperative instillation of chemotherapy with or without
subsequent induction therapy [74]. In the Bladder Cancer
Patterns of Care project, 31.5% of NMIBC patients received
adjuvant intravesical instillation [17].
The management of NMIBC is highly variable due to se-
veral factors, including divergence in treatment-related evi-
dence. A retrospective database analysis examined compli-
ance with established treatment guidelines during the initial
2 years after diagnosis as well as disease-speciﬁc survival after
the initial 2-year period [18, 75]. Of the 4,545 individuals
studied, only 1 received all the guideline-recommended care,
despite level 1 evidence (intravesical therapy) [18]. Indivi-
duals compliant with the measures had a lower risk of mor-
tality(hazardrati:0.4;95%CI:0.18,0.89)comparedtothose
who received fewer than 4 cystoscopies, fewer than 4 cytolo-
gies, and no BCG [75]. This research conﬁrms that there is
generally poor adherence to evidence-based guidelines in the
current NMIBC patient population, and that such adherence
substantially improves outcomes.
8. Economics of Bladder Cancer
Overall, bladder cancer is the ninth-most costly cancer in the
US and was estimated to cost approximately $3.98 billion in
2010 [76]. Assuming a 2% annual increase in direct medical
costs in the initial and ﬁnal phases of care, projected 2020
costs increase to $4.9 billion (in 2010 dollars) [76]. Further-
more, because these cost estimates do not include other
types of costs, such as lost productivity or patient suﬀering,
the total economic burden of bladder cancer is considerably
higher. Based exclusively on direct medical costs, however,
bladdercanceristhemostcostlyofallcancersintermsoflife-
time per-patient treatment costs, which have been estimated
to range from $96,000 to $187,000 per patient in 2001 US
dollars [25]. This high cost of bladder cancer is largely due to
the disease’s high recurrence rate and low mortality rate and
costs associated with disease surveillance [25, 26].
Treatment of complications associated with bladder can-
cer therapy contributes to almost one-third of total costs [2].
Also, treating recurrences constitutes a signiﬁcant portion of
the costs of bladder cancer care, as a recent, retrospective
review of 208 bladder cancer patients estimated that 60%
($39,393) of the lifetime cost per patient ($65,158) was
attributable to surveillance and treatment of recurrences [2].
Thus, prevention of recurrences by adherence to evidence-
based guidelines and development of novel therapies that
decrease rate of recurrence and progression with a better side
eﬀect proﬁle could result in substantial savings to the health-
care system, thereby increasing the importance of additional
research and funding in this area [77].
9. Qualityof Life
Treatment-associated complications not only contribute to
the economic burden of bladder cancer but also increase pa-
tient impairment in physical health and worsened quality of
life [78–80]. Quality of life aﬀecting patient care and patient
satisfaction with treatment options is becoming increasingly
important by the medical community at large [80]. While
there are several quality of life instruments in bladder cancer,
no predominant single index is used widely [81].
Overall, bladder cancer patients report a statistically sig-
niﬁcant decline in physical health compared to control
subjectsandgreatermeanreductionsingeneralwell-beingas
measured by the SF-36 than patients with prostate and breast
cancer [78]. In addition, general health perceptions (as mea-
sured by the SF-36) in NMIBC patients compared with pop-
ulation norms have been shown to be severely impaired [82].
WiththeimplementationoftheﬁrstfewTURBTprocedures,
physical functioning, social functioning, and role-emotional
domains have also been shown to demonstrate impairment
[82].
Two studies that assessed the impact of intravesical instil-
lation on quality of life found that BCG induction resulted in
an acute, moderate deterioration in quality of life following
instillation [83, 84]. Kulkarni et al. [85] estimated the disuti-
lities associated with treatment of NMIBC, quantiﬁed in qu-
ality-adjusted life years (QALYs), and showed that treatment
leads to signiﬁcant decrements in the quality of life. Thus,
eﬀorts to reduce preventable recurrences should lead to sub-
stantial humanistic beneﬁts [86].
10. Conclusion
Bladder cancer is a heterogeneous, highly prevalent disease
that accounts for signiﬁcant morbidity and mortality in the
USA [2, 3]. The high rates of recurrence and risk of disease
progression in bladder cancer often require lifelong surveil-
lance, making the disease both clinically and economically
important [51]. Further research is needed to quantify the
humanistic burden of NMIBC using instruments validated
in the appropriate patient populations.
Even with current therapies, recurrences are common,
and the eﬃcacy of treatments must be balanced with their
toxicity so that no single treatment option can be consid-
ered superior across all NMIBC cancer risk strata and all
individualpatients.Thiscreatesanunmetneedfornewtreat-
ment options associated with fewer complications, better
patient compliance, improved utilization in appropriate sett-
ings, and lower costs [3, 12, 13, 20, 41–43]. Perhaps the
greatestopportunity lies in theuseof perioperative intravesi-
cal therapy, as the large gap between the guideline recom-
mendations and apparent utilization may be improved by
physician adherence to guidelines.6 Advances in Urology
Fortunately, new treatment options that can be used
immediately after surgical removal of bladder tumors in pa-
tients with NMIBC are currently being tested and have been
shown to increase the time to recurrence of disease and are
also associated with less frequent and less severe adverse
events compared to the most commonly used intravesical
therapies [71]. Treatments such as apaziquone may have cli-
nicalandeconomicadvantagesforintravesicaluseinpatients
with NMIBC and may gain wider acceptance among treating
physicians. Further research in the optimal treatment of
NMIBC, from both a clinical and economic standpoint, is
warranted.
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